Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: November 13, 2008
Last updated: February 22, 2017
Last verified: February 2017
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: biphasic insulin aspart 30
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Percentage of subjects achieving HbA1c below 6.5% [ Time Frame: after 16, 32 and 48 weeks, respectively ]

Enrollment: 102
Actual Study Start Date: June 26, 2003
Study Completion Date: November 29, 2004
Primary Completion Date: October 31, 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: biphasic insulin aspart 30
Treat-to-target dose titration scheme
Other Names:
  • NovoLog® Mix 70/30
  • NovoMix®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes mellitus for at least 12 months
  • HbA1c: 7.5-10.0%
  • An antidiabetic regimen that has been stable for at least 3 months
  • Able and willing to perform SMBG testing as per protocol

Exclusion Criteria:

  • Use of any insulin preparations other than NPH or glargine within the past 6 months
  • Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or judged to be using inadequate contraceptive measures (adequate contraceptive measures includes: sterilization, intrauterine devices, oral contraceptives, or consistent use of barrier methods)
  • Known or suspected allergy to trial product or agents related to trial product
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00791895

United States, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85006
United States, California
Novo Nordisk Investigational Site
La Jolla, California, United States, 92093-0694
Novo Nordisk Investigational Site
La Jolla, California, United States, 92093-0831
United States, Florida
Novo Nordisk Investigational Site
Deland, Florida, United States, 32720
United States, Kansas
Novo Nordisk Investigational Site
Wichita, Kansas, United States, 67205
United States, Nebraska
Novo Nordisk Investigational Site
Omaha, Nebraska, United States, 68114
United States, New York
Novo Nordisk Investigational Site
Albany, New York, United States, 12206
United States, Ohio
Novo Nordisk Investigational Site
Cleveland, Ohio, United States, 44115
United States, Oregon
Novo Nordisk Investigational Site
Medford, Oregon, United States, 97504
United States, Tennessee
Novo Nordisk Investigational Site
Memphis, Tennessee, United States, 38119
United States, Texas
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75231
Novo Nordisk Investigational Site
Houston, Texas, United States, 77030
United States, Utah
Novo Nordisk Investigational Site
Ogden, Utah, United States, 84403
United States, Washington
Novo Nordisk Investigational Site
Renton, Washington, United States, 98057
United States, Wisconsin
Novo Nordisk Investigational Site
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT00791895     History of Changes
Other Study ID Numbers: BIASP-2174
Study First Received: November 13, 2008
Last Updated: February 22, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin degludec, insulin aspart drug combination
Insulin, Isophane
Biphasic Insulins
Insulin Aspart
Insulin, Long-Acting
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 28, 2017